Profile of infliximab in the treatment of pediatric Crohn’s disease

Abstract

In recent years, a novel biologic therapy with monoclonal antibodies against tumor necrosis factor-alpha has revolutionized the treatment of Crohn’s disease. Infliximab, the first biologic agent, has been demonstrated to considerably improve both clinical and endoscopic outcomes. In view of the growing popularity of infliximab in the management of Crohn’s disease, we review the profile of the agent in the treatment of this disease in a pediatric setting.

Assessment of systemic genetic damage in pediatric inflammatory bowel disease

“…The US FDA‐approved label for infliximab indicates that genotoxicity was not apparent in pre‐clinical models (Remicade® label, 2013). It is also important to point out that together with other anti‐TNF therapies, infliximab has revolutionized the treatment of IBD (Kierkus et al ., 2015). Therefore, any possible deleterious effects from infliximab must be weighed carefully against the often profound benefits to patients' health and quality of life.…”